Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
NCT06246357Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2024
- Primary completion
- Dec 2029
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pentixafor in hyperaldosteronism, Cushing's syndrome, sponsored by National Cancer Institute. Started Sep 2024; status: recruiting.
02
Drugs
pentixafor
03
Conditions
hyperaldosteronismCushing's syndrome
Beyond the preview
Go deeper on NCT06246357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06246357.